$4.98
4.78% day before yesterday
Nasdaq, Aug 22, 10:16 pm CET
ISIN
US09075P1057
Symbol
BTAI

BioXcel Therapeutics, Inc. Stock price

$4.98
+3.18 175.90% 1M
+3.01 152.79% 6M
-1.00 16.76% YTD
-5.45 52.27% 1Y
-223.66 97.82% 3Y
-594.06 99.17% 5Y
-171.50 97.18% 10Y
-171.50 97.18% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
-0.25 4.78%
ISIN
US09075P1057
Symbol
BTAI
Industry

Key metrics

Basic
Market capitalization
$72.5m
Enterprise Value
$163.7m
Net debt
$91.3m
Cash
$17.4m
Shares outstanding
6.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
83.3 | 50.3
EV/Sales
188.2 | 113.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-242.8%
Return on Equity
64.0%
ROCE
660.8%
ROIC
-
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
$870.0k | $1.4m
EBITDA
$-49.9m | $-45.6m
EBIT
$-50.2m | $-43.8m
Net Income
$-51.0m | $-46.4m
Free Cash Flow
$-55.8m
Growth (TTM | estimate)
Revenue
-63.8% | -36.6%
EBITDA
52.2% | 29.2%
EBIT
52.1% | 32.4%
Net Income
52.8% | 22.1%
Free Cash Flow
47.1%
Margin (TTM | estimate)
Gross
-144.6%
EBITDA
-5,742.7% | -3,169.3%
EBIT
-5,777.9%
Net
-5,869.8% | -3,223.8%
Free Cash Flow
-6,424.5%
More
EPS
$-6.5
FCF per Share
$-8.4
Short interest
4.8%
Employees
37
Rev per Employee
$60.0k
Show more

Is BioXcel Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

BioXcel Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a BioXcel Therapeutics, Inc. forecast:

9x Buy
75%
2x Hold
17%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a BioXcel Therapeutics, Inc. forecast:

Buy
75%
Hold
17%
Sell
8%

Financial data from BioXcel Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.87 0.87
64% 64%
100%
- Direct Costs 2.12 2.12
55% 55%
244%
-1.26 -1.26
221% 221%
-145%
- Selling and Administrative Expenses 23 23
59% 59%
2,654%
- Research and Development Expense 26 26
47% 47%
2,967%
-50 -50
52% 52%
-5,730%
- Depreciation and Amortization 0.31 0.31
0% 0%
36%
EBIT (Operating Income) EBIT -50 -50
52% 52%
-5,765%
Net Profit -51 -51
53% 53%
-5,856%

In millions USD.

Don't miss a Thing! We will send you all news about BioXcel Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioXcel Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August          NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced completion of the database lock for its SERENITY At-Home pivota...
Neutral
GlobeNewsWire
6 days ago
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received p...
Neutral
GlobeNewsWire
11 days ago
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D.
More BioXcel Therapeutics, Inc. News

Company Profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Head office United States
CEO Vimal Mehta
Employees 37
Founded 2017
Website www.bioxceltherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today